Cassava Sciences Inc vs Nvidia Corp — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Nvidia Corp trades at $223.38 (market cap $5.27T). The key difference: Nvidia Corp is far larger — about 110366.5× Cassava Sciences Inc's market cap, and Nvidia Corp pays a 0.46% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | NVDA | |
|---|---|---|
Market Cap | $47.75M | $5.27T |
Sector | Health | Technology |
52-Week High | $4.64 | $235.75 |
52-Week Low | $0.87 | $165.17 |
Enterprise Value | -$34.93M | $5.20T |
Dividend Yield | — | 0.46% |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
NVIDIA (NVDA) trades at $217.56, down 2.86% over the past 24 hours, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.87 exceeding the $1.76 estimate. Revenue surged to $130.50B in 2025, driving a net income margin of 62.97% and robust cash flow from operations of $64.09B. Analyst sentiment remains overwhelmingly positive, with a consensus price target of $325.86.
The outlook for NVDA is favorable, supported by accelerating AI chip demand and a dominant market position. Key opportunities include sustained revenue growth and expanding profitability, while risks involve heightened competition, potential peak AI spending, and market volatility. The stock's current valuation metrics, such as a P/E of 33.31, reflect high growth expectations that must be met to justify further upside.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →